Company

About Hanmi

한미약품은 창조와 도전을 기치로 신약개발에 매진하는 R&D중심 제약기업입니다.

History

2014

  • DecHanmi transfers entecavir synthetic methods to Hwail
  • Hanmi showcases RFID system in 'RFID/USN KOREA 2010'
  • Beijing Hanmi wins Korea-China Corporate Management Grand Prize
  • NovUK MHRA recommends approval of Pidogul
  • OctHanmi submits IND application for Irbesartan-Atorvastatin combo
  • SepHanmi receives IR52 Jang Young-Shil Award from KOITA
  • AugHanmi initiates the clinical trials of Amosartan in Europe
  • Hanmi ranks 1st in R&D investment among Korean pharmaceutical companies
  • Hanmi submits IMPD in Europe for phase I clinical trials of LAPS-Exendin
  • JulAmosartan, approved as the initial therapy among CCB+ARB hypertension combo drugs
  • Hanmi submits IMPD in Europe for phase I clinical trials of LAPS-Exendin
  • MayPhase I underway for Atorvastatin plus Aspirin fixed dose combination drug
  • JunHanmi wins the best drug research award from KDRA
  • AprLAPSCOVERY Platform Technology obtains US Patents
  • Feb's Amosartan ranked the highest for detailing drugs
  • IND Application for long-acting human growth hormone approved
  • JanKFDA Approves IND application of once monthly Exendin4 analog